Sean Ekins - Jan 19, 2023 Form 3 Insider Report for AVITA Medical, Inc. (RCEL)

Signature
/s/ Donna Shiroma, by power of attorney
Stock symbol
RCEL
Transactions as of
Jan 19, 2023
Transactions value $
$0
Form type
3
Date filed
1/24/2023, 04:50 PM
Next filing
Jun 8, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
holding RCEL Common Stock 14.9K Jan 19, 2023 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
holding RCEL Stock Options (Right to Buy) Jan 19, 2023 Common Stock 9K $4.26 Direct F2, F3, F4
holding RCEL Stock Options (Right to Buy) Jan 19, 2023 Common Stock 5K $4.26 Direct F2, F4, F5
holding RCEL Stock Options (Right to Buy) Jan 19, 2023 Common Stock 5K $6.38 Direct F2, F6, F7
holding RCEL Stock Options (Right to Buy) Jan 19, 2023 Common Stock 5K $39.58 Direct F2, F8, F9
holding RCEL Stock Options (Right to Buy) Jan 19, 2023 Common Stock 30K $21.93 Direct F10
holding RCEL Stock Options (Right to Buy) Jan 19, 2023 Common Stock 2.3K $20.21 Direct F11
holding RCEL Stock Options (Right to Buy) Jan 19, 2023 Common Stock 1.65K $18.21 Direct F12
holding RCEL Stock Options (Right to Buy) Jan 19, 2023 Common Stock 7.05K $4.97 Direct F13
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Includes unvested Restricted Stock Units, each representing a contingent right to be issued one share of Common Stock.
F2 These Stock Options were originally exercisable for ordinary shares of Avita Medical, Ltd. ("Predecessor"). Pursuant to a scheme of arrangement, completed on June 30, 2020, the Stock Options became exercisable for shares of Common Stock of the Issuer in the ratio of one share of Common Stock for every 100 ordinary shares of Predecessor for which the Stock Options would otherwise be exercisable.
F3 These Stock Options became exercisable upon the satisfaction of time-based and performance-based vesting criteria.
F4 The exercise price was converted from A$0.056, which reflects the 100:1 consolidation ratio applied in converting ordinary shares of Predecessor to shares of the Issuer's Common Stock, using the exchange rate as in effect on the date of grant (June 12, 2018).
F5 These Stock Options become exercisable in four equal annual installments beginning on June 12, 2019.
F6 These Stock Options become exercisable in four equal annual installments beginning on November 1, 2019.
F7 The exercise price was converted from A$0.089, which reflects the 100:1 consolidation ratio applied in converting ordinary shares of Predecessor to shares of the Issuer's Common Stock, using the exchange rate as in effect on the date of grant (November 1, 2018).
F8 These Stock Options become exercisable in four equal annual installments beginning on October 1, 2020.
F9 The exercise price was converted from A$0.590, which reflects the 100:1 consolidation ratio applied in converting ordinary shares of Predecessor to shares of the Issuer's Common Stock, using the exchange rate as in effect on the date of grant (October 1, 2019).
F10 These Stock Options become exercisable in four equal annual installments beginning on March 17, 2022.
F11 These Stock Options become exercisable in four equal annual installments beginning on July 6, 2022.
F12 These Stock Options become exercisable in four equal annual installments beginning on August 26, 2022.
F13 These Stock Options become exercisable in three equal annual installments beginning on August 20, 2023.